Sinphar Pharmaceutical Co Ltd Market Cap ($182.46 Million)
Market Cap & Net Worth: Sinphar Pharmaceutical Co Ltd (1734)
Sinphar Pharmaceutical Co Ltd market cap. Sinphar Pharmaceutical Co Ltd (TW:1734) has a market capitalization of $182.46 Million (NT$5.79 Billion) as of November 5, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #16707 globally and #816 in its home market, demonstrating a -0.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinphar Pharmaceutical Co Ltd's stock price NT$30.45 by its total outstanding shares 190196773 (190.20 Million). Also see 1734 cash generation efficiency for how efficiently the company converts equity into cash flow.
Sinphar Pharmaceutical Co Ltd Market Cap History (2015–2026)
Sinphar Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $163.72 Million to $182.46 Million (1.16% CAGR). Check 1734 stock price for real-time trading data and today's change.
Sinphar Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinphar Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Sinphar Pharmaceutical Co Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.05x
Sinphar Pharmaceutical Co Ltd's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Sinphar Pharmaceutical Co Ltd's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $139.54 Million | $2.13 Billion | $16.55 Million | 0.07x | 8.43x |
| 2017 | $125.66 Million | $2.13 Billion | $36.73 Million | 0.06x | 3.42x |
| 2018 | $113.07 Million | $2.22 Billion | $8.79 Million | 0.05x | 12.87x |
| 2019 | $114.23 Million | $2.39 Billion | $13.96 Million | 0.05x | 8.18x |
| 2020 | $183.19 Million | $2.39 Billion | -$28.51 Million | 0.08x | N/A |
| 2021 | $171.96 Million | $2.43 Billion | -$38.13 Million | 0.07x | N/A |
| 2022 | $198.64 Million | $2.86 Billion | $224.64 Million | 0.07x | 0.88x |
| 2023 | $203.44 Million | $2.96 Billion | $375.17 Million | 0.07x | 0.54x |
| 2024 | $186.96 Million | $3.15 Billion | $304.70 Million | 0.06x | 0.61x |
| 2025 | $182.76 Million | $3.37 Billion | $365.75 Million | 0.05x | 0.50x |
Competitor Companies of 1734 by Market Capitalization
Companies near Sinphar Pharmaceutical Co Ltd in the global market cap rankings as of November 5, 2026. Also see Sinphar Pharmaceutical Co Ltd (1734) total assets for a full breakdown of the balance sheet.
Key companies related to Sinphar Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Sinphar Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Sinphar Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Sinphar Pharmaceutical Co Ltd's market cap moved from $163.72 Million to $ 182.46 Million, with a yearly change of 1.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$182.46 Million | -0.16% |
| 2025 | NT$182.76 Million | -2.24% |
| 2024 | NT$186.96 Million | -8.10% |
| 2023 | NT$203.44 Million | +2.41% |
| 2022 | NT$198.64 Million | +15.52% |
| 2021 | NT$171.96 Million | -6.13% |
| 2020 | NT$183.19 Million | +60.36% |
| 2019 | NT$114.23 Million | +1.03% |
| 2018 | NT$113.07 Million | -10.02% |
| 2017 | NT$125.66 Million | -9.94% |
| 2016 | NT$139.54 Million | -14.77% |
| 2015 | NT$163.72 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Sinphar Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $182.46 Million USD |
| MoneyControl | $182.46 Million USD |
| MarketWatch | $182.46 Million USD |
| marketcap.company | $182.46 Million USD |
| Reuters | $182.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more